^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IFNL3 (Interferon Lambda 3)

    i
    Other names: IFNL3, Interferon Lambda 3, IL-28B, IL28C, IL28B, Interferon Lambda-3, Cytokine Zcyto22, Interleukin-28B, Interleukin-28C, IFN-Lambda-3, IL-28C, Interleukin 28B (Interferon, Lambda 3), Interferon, Lambda 4, Interleukin 28B, IFN-Lambda-4, ZCYTO22
    Associations

    News

    Trials
    1m
    Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD. (PubMed, Sci Rep)
    Furthermore, serum IFN-λ3 levels at 1 month were significantly lower in the good control group than in the poor control group (p = 0.004). Serum IFN-λ3 levels may reflect short-term treatment response and could serve as a useful sequential biomarker for assessing disease control in patients with anti-MDA5 antibody-positive DM-ILD.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1) • IFNL3 (Interferon Lambda 3)
    5ms
    Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways. (PubMed, medRxiv)
    Finally, among individuals with chronic hepatitis C who underwent antiviral therapy, cirrhosis risk was modified by variants in PNPLA3, IFNL3/4, and CD81 following pegylated interferon-α therapy, and by APOE lead variant following direct-acting antiviral therapy. These findings provide new insights into the complex genetic architecture of CLD progression with potential clinical and therapeutic implications.
    Journal
    |
    FGF21 (Fibroblast Growth Factor 21) • APOB (Apolipoprotein B) • APOE (Apolipoprotein E) • CD81 (CD81 Molecule) • IFNL3 (Interferon Lambda 3) • PNPLA3 (Patatin Like Phospholipase Domain Containing 3)
    7ms
    Genetic polymorphisms of IFNL3 are associated with risk of immune checkpoint inhibitor-related pneumonitis in lung cancer patients. (PubMed, Cytokine)
    IFNL3 rs129798060-TT, rs12980275-GG and rs8099917-GG genotypes were associated with lower serum level of IFN-λ3 and CIP susceptibility in lung cancer patients.
    Journal • Checkpoint inhibition • IO biomarker
    |
    IFNL3 (Interferon Lambda 3)
    7ms
    Interleukin gene polymorphisms (IL1B, IL6, IL10, IL16, IL28B) increase prostate cancer risk and associate with aggressive disease features in Iraqi men: A case-control study. (PubMed, Cancer Epidemiol)
    In this study, we identified proliferative inflammatory lesions of the prostate in Iraqi patients, suggesting that polymorphisms in the IL1B, IL6, IL10, IL16, and IL28B genes significantly increased prostate cancer risk and exacerbated aggressive disease features. These findings suggest the key role of these gene variants in modulating inflammatory and immune responses in the prostate carcinogenesis. Additional research is necessary to investigate these findings in other populations and examine the possibility of using them as risk assessment and personalized treatment biomarkers.
    Journal
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IFNL3 (Interferon Lambda 3) • IL16 (Interleukin 16)
    9ms
    IFN-λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy. (PubMed, Immunology)
    However, the precise mechanisms by which IFN-λ influence immune modulation and disease progression remain an area of active investigation. This review aims to provide an overview of the structure, function and signalling pathways of IFN-λ, exploring their role in immune-related diseases and discussing potential avenues for therapeutic intervention.
    Review • Journal • IO biomarker
    |
    IL10 (Interleukin 10) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3)
    1year
    Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant. (PubMed, Virol J)
    Furthermore, vaccination with CpG-modified mE7/HSP70 and mE6/HSP70 plasmids, alongside the Interleukin-28B (IL-28B) gene adjuvant, generated substantial preventive and therapeutic antitumor effects against HPV E6- and E7-expressing tumors in C57BL/6 mice. These results suggested that integrating these multiple strategies into an HPV DNA vaccine holds promise for effectively controlling HPV infection and related diseases.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNL3 (Interferon Lambda 3)
    over1year
    Copy number variation and clinical response to chemotherapy and bevacizumab in the Czech metastatic colorectal cancer patients. (PubMed, Klin Onkol)
    In the pilot study, we found promising copy number variation biomarkers of bevacizumab response in FFPE samples of mCRC patients. The validation phase should be focused especially on the genes associated with angiogenesis (AGRN, MAPK8, ARHGAP22, LGALS13, LGALS4, ZFP36, and MYC), tumorigenesis (DVL1), and tumor proliferation (IFNL1, IFNL2, IFNL3, MAP3K10, and MAP4K1).
    Journal • Metastases
    |
    LGALS1 (Galectin 1) • MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • LGALS4 (Galectin 4) • AGRN (Agrin) • DVL1 (Dishevelled Segment Polarity Protein 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • MAPK8 (Mitogen-activated protein kinase 8) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    Avastin (bevacizumab)
    over1year
    BEAUTY: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CCR5 (C-C Motif Chemokine Receptor 5) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • HLA-B (Major Histocompatibility Complex, Class I, B) • NLRC5 (NLR Family CARD Domain Containing 5) • FOXP3 (Forkhead Box P3) • IKZF2 (IKAROS family zinc finger 2) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • ITGAX (Integrin Subunit Alpha X) • PRF1 (Perforin 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • TAP1 (Transporter 1) • CCR6 (C-C Motif Chemokine Receptor 6) • CEACAM8 (CEA Cell Adhesion Molecule 8) • DDX58 (DExD/H-Box Helicase 58) • HLA-C (Major Histocompatibility Complex, Class I, C) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • ITGB1 (Integrin Subunit Beta 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    Verzenio (abemaciclib)
    over1year
    Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in Hepatocellular Carcinoma Egyptian patients and relation to genetic polymorphisms. (PubMed, Expert Rev Anticancer Ther)
    Prospective cohort study conducted on 104 eligible HCC Egyptian patients who underwent TACE using doxorubicin and lipiodol. Furthermore, the IL28B rs12979860 (C/T) gene may be associated with the efficacy and prognosis of TACE treatment in HCC Egyptian patients. The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05291338).
    Journal
    |
    ANGPT2 (Angiopoietin 2) • IFNL3 (Interferon Lambda 3)
    |
    doxorubicin hydrochloride
    almost2years
    Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. (PubMed, J Immunother Cancer)
    Our study indicated that IFN-λ3 enables macrophage-mediated phagocytosis and antitumor immune responses and suggests a rationale for using Type III IFN as a predictive biomarker and potential immunotherapeutic candidate for bladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNL3 (Interferon Lambda 3)
    almost2years
    Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology. (PubMed, Neurol Neuroimmunol Neuroinflamm)
    Our work demonstrates the utility of human cell microarray technology to detect known and discover unknown autoantibodies in human serum samples. Despite potential CIDP-associated autoantibodies (anti-LIF and anti-IFNL3) being identified, their clinical and pathogenic relevance needs to be elucidated in bigger cohorts.
    Journal
    |
    EPHA7 (EPH Receptor A7) • CNTN1 (Contactin 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • LIF (LIF Interleukin 6 Family Cytokine)
    2years
    Prognostic role of interferon-lambda 3 in anti-MDA5-positive dermatomyositis-associated ILD. (PubMed, Arthritis Rheumatol)
    Serum IFN-λ3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody-positive DM-ILD.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1) • IFNL3 (Interferon Lambda 3)